Market
Story
FDA Approves Eli Lilly's Zepbound (tirzepatide) as First and Only Treatment for Obstructive Sleep Apnea in Adults with Obesity
Dec 20, 2024, 09:34 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound® (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval marks Zepbound as the first and only prescription medication specifically indicated for this condition in this patient population. The approval was confirmed by multiple sources, highlighting its significance in addressing sleep apnea associated with obesity.
View original story
Similar markets
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 2 million • 25%
1 million to 2 million • 25%
500,000 to 1 million • 25%
Less than 500,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
$500 million to $1 billion • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Less than $500 million • 25%
Less than $10 million • 25%
More than $30 million • 25%
$20 million to $30 million • 25%
$10 million to $20 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%